Effects of supplementation with Curcumin on serum adipokine concentrations: A randomized controlled trial
Nutrition. 2016, DOI: 10.1016/j.nut.2016.03.018
|Metabolic syndrome (MetS), also known as syndrome X, has a worldwide prevalence ranging 10-84 %. It is a bunch of several cardiometabolic risk factors, including abdominal adiposity, hyperglycemia, hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C) and hypertension. Insulin resistance and visceral adiposity are the key factors underlying MetS pathophysiology.|
Owing to its proven and well established diversity of biological activities and several molecular targets, Curcumin has become an interesting phytochemical against a wide range of diseases, including MetS.
Several studies have demonstrated that Curcumin has the potential to modify almost all features of MetS, such as lowering plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), triglyceride and glucose, and increasing those of HDL-C, and also possesses insulin-sensitizing, anti-obesity and anti-hypertensive properties. Curcumin has also been found to be targeting adiponectin and leptin, the most studied adipokines, whose levels are suggested to be altered in patients with MetS.
To evaluate changes in serum levels of adiponectin and leptin, and the ratio of these two adipokines, following Curcumin supplementation in patients with MetS.
Results and Discussion:
Curcumin improved serum levels of adiponectin and leptin, and leptin:adiponectin ratio in patients with MetS, which has encouraged to conduct further detailed studies to ascertain the impact of Curcumin supplementation.